도xorubicin을 투여받는 유방암 환자에서 멜라토닌 대 비타민 D의 심장보호 효과
도xorubicin을 투여받는 유방암 환자에서 멜라토닌 대 비타민 D의 심장보호 효과를 평가하는 임상 연구
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Doxorubicin is one of the most potent chemotherapeutic agents and is widely used for the treatment of various cancers and hematological malignancies . Although Doxorubicin has a potential beneficial effect in cancer treatment, its dose-dependent cardio toxicity is considered a major challenge.
Doxorubicin is known to generate free radicals either by redox cycling between a semiquinone form and a quinone form or by forming a Doxorubicin-Fe3+ complex . In both pathways, molecular oxygen is reduced to superoxide ion , which is converted to other forms of reactive oxygen species such as hydrogen peroxide and hydroxyl radical . These free radicals could then cause membrane and macromolecule damage, both of which lead to injury to the heart, an organ that has a relatively low level of antioxidant enzymes such as superoxide dismutase and catalase .
Furthermore, it was revealed that Doxorubicin may enhance the death of cardiomyocytes by affecting the tumor necrosis factor signaling pathway via increasing the expression and levels of inflammatory genes interleukin and interleukin -6 .
To alleviate DOX-induced toxicity, researchers have tested a number of strategies, including the administration of antioxidants and/or antiapoptotic agents, in both in vitro and in vivo models of Doxorubicin induced cytotoxicity, but most of these trials have failed to translate into clinical benefits . As a result, there are no effective approaches for alleviating Doxorubicin induced cytotoxicity despite intensive research over recent decades .
Melatonin is a natural hormone that is primarily secreted by the pineal gland and functions as a major regulator of circadian rhythms in humans . Melatonin also plays a variety of biological roles as a modulator of mood, sexual behavior and sleep; low levels or a deficiency of melatonin are also associated with Parkinson's disease, Alzheimer's disease, epilepsy, ischemic injury, diabetes, and even cancer .
Melatonin has emerged as a promising adjuvant that protects against doxorubicin-induced cytotoxicity, as highlighted by various studies and clinical trials that have demonstrated cardioprotective effects against several chemotherapeutic agents . Moreover, melatonin exhibits low toxicity and easily enters cells owing to its good solubility in both aqueous and organic phases and its highly lipophilic properties . Vitamin D plays an important role in the regulation of body function including the cardiovascular system .
Vitamin D deficiency results in the decrease of active calcitriol leading to inhibition of proliferation of cardiomyocytes and vascular smooth muscles .
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Tanta, 이집트
- Tanta University
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age from 18 to 65 years old.
- Gender: female.
- Positive breast cancer women who are scheduled to receive Doxorubicin.
- Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.
- Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.
- Normal renal and liver function tests.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Women with HER-2 positive of breast cancer.
- Formerly treated with Doxorubicin.
- Patients with a known hypersensitivity to any of the used drugs.
- On other concomitant vitamins or food supplements.
- Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.
- Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction < 50%.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Group 1 (Doxorubicin group)
30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks. |
30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks. |
|
실험적: Group 2 (Vitamin D group)
patients with Vitamin D supplementation (1000 iu/day) plus Doxorubicin for 12 weeks |
patients with Vitamin D supplementation (1000 iu/day) plus traditional therapy for 12 weeks |
|
실험적: Group 3 (melatonin group)
30 patients with 10 mg of melatonin orally, once daily plus Doxorubicin for 12 weeks. |
patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Decreasing incidence and severity of cardiotoxicity
기간: 12 weeks
|
Assessment of decreasing incidence and severity of cardiotoxicity by echocardiogram and ejection fraction is associated with doxorubicin treatment. |
12 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Plasma B-Type Natriuretic Peptide (BNP) Concentration
기간: Baseline and 12 weeks.
|
Change in plasma B-type natriuretic peptide (BNP) concentration from baseline to 12 weeks, measured using a chemiluminescent microparticle immunoassay (CMIA) on the Abbott Alinity i analyzer. Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in pg/mL. |
Baseline and 12 weeks.
|
|
Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentration
기간: Baseline and 12 weeks.
|
Change in serum/plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline to 12 weeks, measured using a chemiluminescent microparticle immunoassay (CMIA) on the Abbott Alinity i analyzer. Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in pg/mL. |
Baseline and 12 weeks.
|
|
Change in High-Sensitivity Cardiac Troponin I (hs-cTnI) Concentration
기간: Baseline and 12 weeks.
|
Change in serum/plasma high-sensitivity cardiac troponin I (hs-cTnI) concentration from baseline to 12 weeks, measured using the Alinity i STAT High Sensitive Troponin-I chemiluminescent microparticle immunoassay (CMIA). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/L. |
Baseline and 12 weeks.
|
|
Change in Myeloperoxidase (MPO) Concentration
기간: Baseline and 12 weeks.
|
Change in myeloperoxidase (MPO) concentration from baseline to 12 weeks, measured using a human MPO double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; SunRed Biological Technology Co., Ltd.). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/mL. |
Baseline and 12 weeks.
|
|
Change in Interleukin-6 (IL-6) Concentration
기간: Baseline and 12 weeks.
|
Change in interleukin-6 (IL-6) concentration from baseline to 12 weeks, measured using a human IL-6 double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; SunRed Biological Technology Co., Ltd.). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/L. |
Baseline and 12 weeks.
|
|
Change in Creatine Kinase-MB (CK-MB) Concentration
기간: Baseline and 12 weeks.
|
Change in serum/plasma creatine kinase-MB (CK-MB) concentration from baseline to 12 weeks, measured using the Alinity i STAT CK-MB chemiluminescent microparticle immunoassay (CMIA). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/mL. |
Baseline and 12 weeks.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- 36265MD408/5/25
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
All data will be available when needed
IPD 공유 지원 정보 유형
- 연구_프로토콜
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .